Environment And Sanitation Tenders

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Substance Guselkumab, Atc L04ac16 for the Period December 1St, 2022 - November 30Th, 2024

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Vildagliptin Metformin, Atc A10bd08 for the Period December 1St, 2022 - November 30Th, 2024

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Botulinum Toxin Type A, Atc M03ax21 for the Period December 1St, 2022 - November 30Th, 2024

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Vildagliptin (A10bh02) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Medicinal Products with the Active Ingredient Paliperidone (N05ax13) and the Trade Name Trevicta(R) (Open House Model).

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Iron(Iii) Sodium Gluconate Complex (B03ac07) as Part of an Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Pirfenidone (L04ax05) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Permethrin (P03ac04) as Part of a So-Called Open House Model.

Hiring of External Technical Control Agency (oct) and External Control of the Energy Efficiency Certification (cee)

Fd2020-22-01129